Decoy Therapeutics Inc. (DCOY)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 600K 1.2M 1.8M Q4 '18: 163.1K Q1 '19: 655.6K Q2 '19: 895.8K Q3 '19: 874.9K Q4 '19: 1M Q1 '20: 1.1M Q2 '20: 1.2M Q3 '20: 1.4M Q4 '20: 1.5M Q1 '21: 1.3M Q2 '21: 571.4K Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '25: 0 Q2 '26: 227.6K Q1 '19 Q4 '19 Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q2 '26

Gross Profit Quarterly

0 300K 600K 900K Q1 '17: 163.4K Q2 '17: 190.2K Q3 '17: 264.8K Q4 '17: 149.5K Q1 '18: 94.6K Q2 '18: 65.6K Q3 '18: 377.1K Q4 '18: 88.1K Q1 '19: 608.3K Q2 '19: 859.6K Q2 '17 Q4 '17 Q2 '18 Q4 '18 Q2 '19

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-15M -10M -5M 0 5M 10M 15M Q3 '21: -3.7M Q4 '21: -4.1M Q1 '22: -6.1M Q2 '22: -4.8M Q3 '22: -14.5M Q4 '22: -6.5M Q1 '23: -5.4M Q2 '23: -4M Q3 '23: -2.5M Q4 '23: -970.7K Q1 '24: -1.8M Q2 '24: -1.5M Q3 '24: -1M Q4 '24: -1.5M Q1 '25: -1.7M Q2 '25: -965.6K Q3 '25: -895.1K Q4 '25: -9M Q1 '26: -2.3M Q2 '26: -2.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-15M -10M -5M 0 5M 10M 15M Q3 '21: -3.7M Q4 '21: -4.1M Q1 '22: -6.1M Q2 '22: -4.7M Q3 '22: -14.4M Q4 '22: -6.4M Q1 '23: -5.3M Q2 '23: -3.9M Q3 '23: -2.4M Q4 '23: -881.8K Q1 '24: -1.7M Q2 '24: -1.4M Q3 '24: -972.1K Q4 '24: -1.5M Q1 '25: -1.7M Q2 '25: -957.8K Q3 '25: -873.5K Q4 '25: -9M Q1 '26: -2.2M Q2 '26: -2.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 70K 140K 210K Q1 '17: 79.1K Q2 '17: 145.3K Q3 '17: 148.8K Q4 '17: 133.3K Q1 '18: 83.9K Q2 '18: 179.9K Q3 '18: 91.9K Q4 '18: 74.9K Q1 '19: 47.3K Q2 '19: 36.1K Q2 '17 Q4 '17 Q2 '18 Q4 '18 Q2 '19

Operating Cash Flow Quarterly

-6M -4M -2M 0 2M 4M 6M Q3 '21: -1.6M Q4 '21: -2.7M Q1 '22: -3.5M Q2 '22: -3.6M Q3 '22: -5.7M Q4 '22: -4.7M Q1 '23: -3.2M Q2 '23: -4.4M Q3 '23: -3.7M Q4 '23: -1.5M Q1 '24: -1.4M Q2 '24: -1.1M Q3 '24: -1.4M Q4 '24: -742.5K Q1 '25: -1.2M Q2 '25: -862.3K Q3 '25: -1.6M Q4 '25: -1.1M Q1 '26: -2.9M Q2 '26: -2.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-16M -8M 0 8M 16M 24M Q2 '14: -3.3M Q1 '15: -4.2M Q2 '15: -4.5M Q3 '15: -6.9M Q4 '15: -5.5M Q1 '16: -9.3M Q2 '16: -9.5M Q3 '16: -7.5M Q4 '16: -6.3M Q1 '17: -8.2M Q2 '17: -5.7M Q3 '17: -8.1M Q4 '17: -5.8M Q1 '18: -9.4M Q2 '18: -8.3M Q3 '18: 21.5M Q4 '18: 387.5K Q1 '15 Q4 '15 Q3 '16 Q2 '17 Q1 '18 Q4 '18

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '20: 14M Q3 '20: 18M Q1 '21: 30.6M Q2 '21: 44.8M Q3 '21: 1.8M Q1 '22: 1.9M Q2 '22: 2.1M Q3 '22: 2.2M Q1 '23: 2.4M Q2 '23: 338.6K Q3 '23: 469.3K Q1 '24: 524.3K Q2 '24: 600.4K Q3 '24: 85.5K Q1 '25: 7.1K Q2 '25: 11.8K Q3 '25: 481.6K Q1 '26: 532K Q2 '26: 532K Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-140.00 -70.00 0.00 70.00 140.00 210.00 Q3 '20: -0.89 Q4 '20: -0.55 Q1 '21: -0.39 Q2 '21: -0.33 Q3 '21: -2.32 Q4 '21: -4.53 Q1 '22: -7.77 Q2 '22: -9.90 Q3 '22: -14.22 Q4 '22: -14.66 Q1 '23: -13.59 Q2 '23: -22.84 Q3 '23: -21.64 Q4 '23: -18.92 Q1 '24: -19.96 Q2 '24: -10.88 Q3 '24: -17.05 Q4 '25: -129.10 Q1 '26: 106.79 Q2 '26: 183.54 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.